OREANDA-NEWS. March 07, 2012. JSC "Grindeks" informs that "Grindeks" today, on 1 March, was visited by the Latvian Minister of Health Ingrida Circene, who met with the management representatives – Chairman of the Board Juris Bundulis, Board Member and Director of the Final Dosage Forms Manufacturing Lipmans Zeligmans, Board Member and Chief Finance and Administrative Officer Vadims Rabsa, Director of the Active Pharmaceutical Ingredients Business Structure Andris Jegorovs.

In "Grindeks", Minister of Health Ingrida Circene visited manufacturing units of  active pharmaceutical ingredients and final dosage forms, as well as industrial waste water treatment plant. During the meeting, a discussion on health and pharmaceutical sector topical issues was held, focusing on the promotion of development of the national pharmaceutical industry, pharmaceutical business environment arrangement and activity of competence centres, in which also "Grindeks" is actively participating.

Latvian Minister of Health Ingrida Circene:  “Today, I was convinced once again that the basis of the competitiveness is efficiency and quality. The leading pharmaceutical company in the Baltic states "Grindeks" is the pride not only in the scale of Latvia, but also a great example for many European companies. It with its activity confirms that the pharmaceutical manufacturing is one of the best export sectors in Latvia.”

Chairman of the Board of JSC "Grindeks" Juris Bundulis: “From manufactured medications and active pharmaceutical ingredients "Grindeks" exports 95%, but for us it is very important to provide with high-quality products the local patients. Despite that the local pharmaceutical manufacturing companies total market share in Latvia is less than 5%, "Grindeks" is optimistic about development opportunities. We have the capability to grow in Latvia and in the Baltic states as a whole. Therefore we strongly support the Health Ministry initiatives that promote business environment arrangement in the pharmaceutical sector, observing the principles of high ethics and fair competition.”